On July 22, Kelun-Biotech rose 3.03% in regular trading, trading at 520.5 HKD/share, with turnover of approximately 145 million HKD.

On the news front, multiple international investment banks recently raised target prices for the company. JPMorgan lifted its target from 535 HKD to 648 HKD, while Goldman Sachs raised its target to 582.95 HKD and maintained a Buy rating, citing optimism for the global commercialization prospects of the core product sac-TMT. Goldman Sachs raised its probability of success for the Lung06 study from 81% to 90% and lifted overseas first-line NSCLC indication success probability from 54% to 63%.

Simultaneously, several top public fund managers including Huatianfu have been aggressively accumulating Hong Kong-listed innovative drug stocks. Kelun-Biotech's public fund shareholding ratio has touched the 5% statutory disclosure threshold following these purchases, reinforcing market confidence through sustained long-term institutional capital inflows. This wave of institutional positioning reflects professional investors' recognition of the innovative drug sector's valuation recovery and long-term value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)